Recent advances in molecular biology have provided insight into the complex network of interaction that occurs within the immune system. The use of specific Immunomodulators to strengthen a deficient immune system or bolster a normal immune system presents a unique strategy for the treatment of various disorders that will clearly affect the practice of clinical medicine for many years to come. A major difficulty limiting the use of immunomodulators in clinical medicine has been the complexity of the immunoregulatory network in which modulation of one component usually perturbs the entire system, thus diminishing the specificity of the approach. Several immunomodulators are currently being tested in the treatment of the immune defect of the acquired immunodeficiency syndrome.
INTRODUCTION
'Synergy and serendipity often play a big part in medical and scientific advances. ' 
Julie Bishop
Immunomodulators weaken or modulate the activity of the immune system that, in turn, decreases the inflammatory response. These drugs are appropriate for subjects who have:
• No respond to aminosalicylates, antibiotics or corticosteroids.
• Steroid-dependent disease or frequently required steroids.
• Experienced side effects with corticosteroid treatment.
• Perennial disease that does not respond to antibiotics.
• Fistulas (abnormal channels between two loops of intestine or between the intestine and another structure).
• A need to maintain remission.
An immunomodulator may be combined with a corticosteroid to speed up response during active flares of disease. Lower doses of the steroid are required in this case, producing fewer side effects. Corticosteroids also may be withdrawn more rapidly when combined with immunomodulators. For that reason, immunomodulators are sometimes referred to as 'steroid-sparing' drug.
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Types of Immunomodulators
Immunosuppressants
Drugs which are used to suppress the immunity (Tables 1  and 2 ). Since, immunity confers resistance to disease, the use of drugs for deliberately suppressing it appears odd at first sight. However, according to the present concept, the ability of the body to recognize self from nonself or foreign, which is the basis of immunity, is liable to cause disorders due to failure to recognize and tolerate antigens produced by its own tissues.
Immunosuppressants Immunostimulants
Mechanism of action
Mechanism of Action of Immunosuppressive Drugs
Generation of humoral and cell-mediated immune response and sites of action of immunosuppressant drugs (Fig. 1) . The antigen (Ag) is processed by macrophages or other antigen presenting cells (APC), coupled with class II major histocompatibility complex (MHC) and presented to the CD4 helper cell which are activated by interleukin-I (IL-I), proliferate and secrete cytokines-these in turn promote proliferation and differentiation of antigen activated B cells into antibody (Ab) secreting plasma cells. Antibodies finally bind and inactivate the antigen.
In cell-mediated immunity-foreign antigen is processed and presented to CD4 helper T cells which elaborate IL-2 and other cytokines that in turn stimulate proliferation and maturation of precursor cytotoxic lymphocytes (CTL) that have been activated by antigen presented with class I MHC. 
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Immunostimulants
The use of a variety of agents to enhance immunological and nonspecific host defences and thus to modify the 
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defences favorably is an exciting development in immunopharmacology (Table 3) .
There has been significant progress in the search for selective immunomodulation; the most significant advance in immunotherapy has been the reduction in systemic glucocorticoids exposure along with early or concomitant introduction of immunosuppressive and immunomodulatory adjuvants.
Cytotoxic and and antimetabolic agents act through the inhibition and/or interruption of cell cycle. These drugs are used to treat serious, life threatening and recalcitrant diseases of the head, neck and face region.
Immunomodulators have a low therapeutic index (narrow window between the toxic and therapeutic range) and intra-and interindividual variation of the pharmacokinetics of these agents. These obstacles are usually overcomed by precise drug dosing (ideal/lean body weight and body surface area) as well as close monitoring of drug levels (parent and metabolite serum peak and trough levels) and organ toxicity.
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DISCUSSION
The growth of clinical immunology has uncovered increasing number of diseases that are due to eccentric immune responses. This has resulted in a search for drugs capable of restyling these unwanted responses. Over the past two decades, considerable progress has been made in identifying a group of compounds capable of modulating immune responses. Experience with immunomodulators in controlled clinical trial is currently limited, but many of these are effective for the treatment of malignant, infectious and immunologic disorders. However, since our understanding of the complex role of such agents in the immune system is still incomplete, the rational design of clinical studies remains a significant challenge. The eventual goal in this area is to develop specific immunomodulation or tolerance directed only at the immune response to selected antigens. This currently remains an elusive goal. Future research should likely focus on molecular and gene level mechanism to achieve the goal.
CONCLUSION
Topical corticosteroids have always been the mainstay therapy for malignant, immunological and infectious disorders since their introduction decades ago. Unfortunately, they are associated with the aftermaths. In recent years, with the debutante of immunomodulators, a collateral therapy for corticosteroids has come into materialization which has aided in the 'steroid-sparing effects'. Thus, we as oral diagnosticians should encourage the use of these supplementary drugs so as to curb the monopoly of steroids and contribute toward the betterment of mankind.
